Erika Martinez, MD’s Post

Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. At #ASCO24, Dr. David Cognetti presented the updated safety and efficacy findings from an interim evaluation of Rakuten Medical’s open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Based on these results, Rakuten Medical plans to initiate a new phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox

Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) https://lnkd.in/e5_Skwv2

Advancing #LiverCancer Diagnosis: Jie Ren et al.'s meta-analysis in #EuropeanRadiology offers valuable insights into using SonoVue® and Sonazoid® for CEUS in detecting hepatocellular carcinoma. Precision in every scan! 🎯🩺 #MedicalImaging 🔗 https://buff.ly/3TKBIg2

A 90-year-old female patient presented with a three-centimeter squamous cell carcinoma (SCC). The patient underwent electronic brachytherapy treatment schedule with Xstrahl Radiant. See the dramatic before and after photos: https://lnkd.in/eZfZGmnu #ThisIsSkinCancer #NMSC #NMSCAwareness #SkinCancerAwarenessMonth  #Xstrahl #RadiantAura #SkinCancer #SkinCancerTreatment #SkinCancerAwareness #squamouscellcarcinoma

Be sure to read this #clinicalinvestigation 🔍 #Percutaneous Microwave #Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes https://lnkd.in/dPfTsF2C

Activation of p53 Signaling and Regression of Breast and Prostate Carcinoma Cells by Spirooxindole-Benzimidazole Small Molecules https://lnkd.in/dFZ5H3sx

This #radiomics model can be used as a non-invasive tool to predict the Leibovich risk groups for patients with localized clear cell renal cell carcinoma. (Huayun Liu et al.) #InsightsIntoImaging Read it here ➡️ https://buff.ly/3tHTqG4

Data on the use of rigosertib in patients with RDEB-associated squamous cell carcinoma was presented at the EADV Congress last week: https://lnkd.in/eEuUDJQF EB-associated squamous cell carcinoma is a leading cause of premature death in patients with RDEB, so while we search for a cure, we must also search for treatments to prevent and slow the progression of EB-associated SCC. We are pleased to support this promising work - you can read more about the trial in the Current Research section of our website. #CureEB #ResearchtheCure #EBResearch #Research #RDEB #EADV23

Clinical response of T3 squamous cell carcinoma of the tongue, treated with neoadjuvant pembrolizumab-carboplatin-paclitaxel. Significant reduction of the tumor size.

Going to #ESMO23? We will be there from Oct 20-23. Come to booth 726a and explore the past, present, and potential future treatment options for unresectable hepatocellular carcinoma (uHCC). Plus, you can make an appointment to discuss the latest data. See you soon! https://hubs.ly/Q024bqv90 #ElevatingOutcomes #EveryMeasureMatters #ElevarAtESMO23